The utility of tissue transglutaminase as a marker of apoptosis during treatment and progression of prostate cancer

Journal of Urology

Volumn 162, Issue 6, 1999, Pages 2165-2169

  Rittmaster, Roger S ^a,b   Thomas, Lynn N ^a   Wright, A Stuart ^a   Murray, Shawn K ^a   Carlson, Kevin ^a   Douglas, Robert C ^a   Yung, Jason ^a   Messieh, Mary ^a   Bell, David ^a   Lazier, Catherine B ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Antiandrogens; DNA fragmentation; Immunohistochemistry; Ki 67 antigen; Prostatic hyperplasia

Indexed keywords

CYPROTERONE ACETATE; DNA FRAGMENT; FLUTAMIDE; GONADORELIN AGONIST; KI 67 ANTIGEN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE;

ANALYTIC METHOD; APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; HORMONE DEPENDENCE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; PROSTATECTOMY;

EID: 0032746018     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)68153-0     Document Type: Article

References (20)

1. Huggins, C. and Hodges, C. V.: Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J. Clin., 22: 232, 1972.
2. Gittes, R. F.: Carcinoma of the prostate. N. Engl. J. Med., 324: 236, 1991.
3. Pettaway, C. A.: Prognostic markers in clinically localized prostate cancer. Tech. Urol., 4: 35, 1998.
4. English, H. F., Kyprianou, N. and Isaacs, J. T.: Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. Prostate, 15: 233, 1989.
5. Piacentini, M., Autuori, F., Dini, L., Farrace, M. G., Ghibelli, L., Piredda, L. and Fesus, L.: "Tissue" transglutaminase is specifically expressed in neonatal rat liver cells undergoing apoptosis upon epidermal growth factor stimulation. Cell Tissue Res., 263: 227, 1991.
6. Gerdes, J., Lemke, H., Baisch, H., Wacker, H. H., Schwab, U. and Stein, H.: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J. Immunol., 133: 1710, 1984.
7. Gavrieli, Y., Sherman, Y. and Ben-Sasson, S. A.: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol., 119: 493, 1992.
8. Rittmaster, R. S., Norman, R. W., Thomas, L. N. and Rowden, G.: Evidence for atrophy and apoptosis in the prostates of men given finasteride. J. Clin. Endocrinol. Metab., 81: 814, 1996.
9. Maeda, O., Kinouchi, T., Meguro, N., Saiki, S., Kuroda, M., Usami, M., Wada, A. and Kotake, T.: Adjunctive value of cell proliferation but not of apoptosis to interpret pathologic effects on prostatic cancer after neoadjuvant endocrine therapy. Jpn. J. Clin. Oncol., 28: 262, 1998.
10. Oomens, E. H., van Steenbrugge, G.: J., van der Kwast, T. H. and Schroder, F. H.: Application of the monoclonl antibody Ki-67 on prostate biopsies to assess the fraction of human prostatic carcinoma. J. Urol., 145: 81, 1991.
11. Colecchia, M., Frigo, B., Del Boca, C., Guardamagna, A., Zucchi, A., Colloi, D. and Leopardi, O.: Detection of apoptosis by the TUNEL technique in clinically localised prostatic cancer before and after combined endocrine therapy. J. Clin. Pathol., 50: 384, 1997.
12. Montironi, R., Pomante, R., Diamanti, L. and Magi-Galluzzi, C.: Apoptosis in prostatic adenocarcinoma following complete androgen ablation. Urol. Int., 60: 25, 1998.
13. Stapleton, A. M., Zbell, P., Kattan, M. W., Yang, G., Wheeler, T. M., Scardino, P. T. and Thompson, T. C.: Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Cancer, 82: 168, 1998.
14. Bubendorf, L., Sauter, G., Moch, H., Schmid, H. P., Gasser, T. C., Jordan, P. and Mihatsch, M. J.: Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J. Pathol., 178: 437, 1996.
15. Bettencourt, M. C., Bauer, J. J., Sesterhenn, I. A., Mostofi, F. K., McLeod, D. G. and Moul, J. W.: Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J. Urol., 156: 1064, 1996.
16. Mashal, R. D., Lester, S., Corless, C., Richic, J. P., Chandra, R., Propert, K. J. and Dutta, A.: Expression of cell cycle-regulated proteins in prostate cancer. Cancer Res., 56: 4159, 1996.
17. Moul, J. W., Bettencourt, M. C., Sesterhenn, I. A., Mostofi, F. K., McLeod, D. G., Srivastava, S. and Bauer, J. J.: Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Surgery, 120: 159, 1996.
18. Koivisto, P., Visakorpi, T., Rantala, I. and Isola, J.: Increased cell proliferation activity and decreased cell death are associated with the emergence of hormone-refractory recurrent prostate cancer. J. Pathol., 183: 51, 1997.
19. Tamboli, P., Amin, M., Schultz, D., Linden, M. and Kubus, J.: Comparitive analysis of the nuclear proliferative index (Ki-67) in benign prostate, prostatic intraepithelial neoplasia, and prostatic carcinoma. Mod. Pathol., 9: 1015, 1996.
20. Westin, P., Stattin, P., Damber, J. E. and Bergh, A.: Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors. Am. J. Pathol., 146: 1368, 1995.